SpecificiT Pharma develops personalized hematological cancer immunotherapies by using Minor Histocompatability Antigens (MiHAs) which enable donor T-cells to be safely directed to eliminate cancer cells following allogeneic hematopoietic cell transplantation (AHCT).
SpecificiT Pharma Inc.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://in.linkedin.com/company/specificit-pharma-inc” connections=”true” suffix=””]
SpecificiTs unique approach is centered on the use of Minor Histocompatability Antigens (_MiHAsÓ) which enable donor T-cells to be safely directed to eliminate cancer cells in a patient.
In Sep 2017, SpecificiT Pharma completed seed financing by existing shareholder AmorChem, along with new partners, Sanderling Ventures and Accel-Rx Health Sciences Accelerator.